News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sensus Healthcare Announces Health Canada Approval


11/16/2012 10:36:19 AM

BOCA RATON, Fla., Nov. 16, 2012 /PRNewswire/ -- SensusHealthcare, providers of the SRT-100, the leading alternative for non surgical skin cancer treatment, announces that it has received a Medical Device License from Health Canada, permitting the marketing and sale of its device for treating skin cancer patients. The SRT-100 is a state-of-the-art therapy device for Non Melanoma Skin Cancer. The SRT-100 provides patients with a virtually pain-free non-invasive treatment option, while achieving excellent clinical outcomes that are comparable to surgery, and without scarring. Sensus Healthcare has reintroduced superficial radiotherapy (SRT) and is the leader in the global clinical community. The SRT-100 is proven to be a viable, safe, and cost-effective modality to treat non-melanoma skin cancers in hospitals and private practice settings.

"We are excited to offer this leading technology alternative to the many patients throughout Canada who are diagnosed with skin cancer. We consider Canada as one of the foremost authorities in providing cost effective technologies and we are delighted to have the SRT-100 considered as a viable choice. We are looking forward to working with Canada's healthcare professionals," stated Joe Sardano, President/CEO, Sensus Healthcare.

SRT-100 is an ideal treatment modality for non-melanoma skin cancers, thanks to its SharpBeam characteristics, where only the targeted lesion is being treated, while the surrounding and underlying healthy tissue is spared. The SRT-100 is FDA, CE, Health Canada, and SFDA cleared and is manufactured in the United States of America under the stringent ISO-13485 and GMP quality standards.

About Sensus Healthcare:
Sensus Healthcare specializes in making proven non-melanoma skin cancer solutions more accessible to patients. Our dedicated superficial radiation therapy (SRT) systems are designed specifically to provide an alternative to surgical procedures for basal cell and squamous cell carcinomas. Our mobile, compact SRT-100 systems are used widely by oncologists and dermatologists to bring non-melanoma skin cancer treatment to more patients in more settings.                                                                                                                           

Media Contact:
Michelle Verina
Public Relations
561-922-5808 Ext. 10
michelle@sensushealthcare.com

SOURCE Sensus Healthcare


Read at BioSpace.com


comments powered by Disqus
   
Melanoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES